Healthcare · NSE/BSE: NEULANDLAB
Neuland Laboratories Limited
Pharmaceuticals
Market Cap ₹0.21L Cr
Verdict: High
Quality Scores
Multi-Bagger
82/100
Compounder Quality
87/100
Management Credibility
88/100
Governance
82/100
Cash Flow Quality
90/100
AI Summary
Neuland Laboratories has evolved from a commoditized API manufacturer (Prime APIs) into a sophisticated high-margin player with a dominant focus on CMS (Custom Manufacturing Solutions) and Specialty APIs. Over the last 10 years, revenue has grown at a 15% CAGR, while PAT has surged at a 30% CAGR, indicating significant operating leverage and a move up the value chain. The company’s recent performance (FY23-FY26 estimates) shows a structural shift in EBITDA margins from historically low teens to the 25-40% range. This transformation is driven by a focus on complex chemistry and late-stage…
Top Opportunities
- Exceptional 5-year profit CAGR of 39%
- Successful pivot from low-margin APIs to high-margin CMS/Specialty
- Robust ROCE exceeding 25% in peak years
Top Risks
- High inventory days (247 days) leading to working capital intensity
- Volatile net profit margins due to high tax spikes in historical years
- Significant capex in 2025-2026 leading to negative FCF
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.